A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 4, 2013, Pages 747-755

  Feld, Ronald ^a   Woo, Margaret M ^b   Leighl, Natasha ^a   Shepherd, Frances A ^a   Beck, J Thaddeus ^c   Zhao, Lihui ^b   Gazi, Lucien ^b   Hengelage, Thomas ^b   Porro, Maria Grazia ^b   Nayak, Asha ^d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Highlands Oncology Group   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

CYP2D6; Dextromethorphan; Panobinostat; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DEXTRORPHAN; PANOBINOSTAT;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BRAIN HEMORRHAGE; CANCER FATIGUE; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CYP2D6 GENE; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENZYME SUBSTRATE; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENOTYPING TECHNIQUE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOTHYROIDISM; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; ONCOGENE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; QT PROLONGATION; TANDEM MASS SPECTROMETRY; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

AGED; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DEXTRORPHAN; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXAMIC ACIDS; INDOLES; MALE; MIDDLE AGED; NEOPLASMS; TANDEM MASS SPECTROMETRY;

EID: 84885383875     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2237-3     Document Type: Article

References (27)

1. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784
2. Atadja P (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 280:233-241
3. Witt O, Deubzer HE, Milde T, Oehme I (2009) HDAC family: what are the cancer relevant targets? Cancer Lett 277:8-21
4. Alsina M, Schlossman RL, Weber DM, Coutre SE, Lonial S, Gasparetto C, Warsi G, Ondovik MS, Mukhopadhyay S, Paley CS, Richardson PGG (2012) PANORAMA 2: a phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma. ASCO Meet Abstr 30:8012
5. San-Miguel JF, Moreau P, Yoon S, Dimopoulos MA, VT de M Hungria, Wiktor-Jedrzejczak W, Elghandour A, Corradini P, Gunther A, Beksac M, Yong K, Lee JH, Lonial S, Hou J, Einsele H, Wroclawska-Swacha M, Weber H, Bourquelot P, Richardson PG (2012) Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1). ASCO Ann Meet Abstr e18572
6. Clive S, Woo MM, Nydam T, Kelly L, Squier M, Kagan M (2012) Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer Chemother Pharmacol 70:513-522
7. Hamberg P, Woo MM, Chen LC, Verweij J, Porro MG, Zhao L, Li W, van der Biessen D, Sharma S, Hengelage T, de Jonge M (2011) Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol
8. Shapiro GI, Frank R, Dandamudi UB, Hengelage T, Zhao L, Gazi L, Porro MG, Woo MM, Lewis LD (2012) The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer. Cancer Chemother Pharmacol 69:555-562
9. Woo MM, Culver K, Li W, Liu A, Scott J, Parker K, Jalaluddin M, Laird G, Cooper MR, Schran HF (2008) Panobinostat (LBH589) pharmacokinetics (PK): implication for clinical safety and efficacy. Ann Oncol 19:viii161 [abstract 487P]
10. Gonzalez FJ, Lee YH (1996) Constitutive expression of hepatic cytochrome P450 genes. FASEB J 10:1112-1117
11. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526
12. Kohler D, Hartter S, Fuchs K, Sieghart W, Hiemke C (1997) CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics 7:453-461
13. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA, Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group, FDA Center for Drug Evaluation and Research (CDER) (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832
14. Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 48:689-723
15. Nielsen MD, Brosen K, Gram LF (1990) A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br J Clin Pharmacol 29:299-304
16. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295
17. Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3:229-243
18. Pope LE, Khalil MH, Berg JE, Stiles M, Yakatan GJ, Sellers EM (2004) Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol 44:1132-1142
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
20. Gorski JC, Jones DR, Wrighton SA, Hall SD (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 48:173-182
21. Obach RS, Walsky RL, Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255
22. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2012) Guidance for industry: Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. In: http://www.fda.gov Web site. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM292362.pdf. Accessed 02/29 2012
23. Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA (1996) The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther 60:295-307
24. Yu A, Haining RL (2001) Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos 29:1514-1520
25. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, Mita M, Beck J, Burris H, Ryan G, Atadja P, Butterfoss D, Dugan M, Culver K, Johnstone RW, Prince HM (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14:4500-4510
26. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, Harrison SJ, Kirschbaum M, Johnston P, Gallagher J, Le Corre C, Shen A, Engert A (2012) Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 30:2197-2203
27. U.S. Food and Drug Adminstration (2013) Drug Interactions & Labeling http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ DrugInteractionsLabeling/ucm080499.htm